SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020–July 2022
American Journal of Epidemiology · 2025
DOI: 10.1093/aje/kwae125 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, 2025. Verfasst von Joshua G Petrie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI 54449, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral, Rural Population. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.
Abstract (Originalsprache)
Studies of SARS-CoV-2 incidence are important for response to continued transmission and future pandemics. We followed a rural community cohort with broad age representation with active surveillance for SARS-CoV-2 identification from November 2020 through July 2022. Participants provided serum specimens at regular intervals and after SARS-CoV-2 infection or vaccination. We estimated the incidence of SARS-CoV-2 infection identified by study reverse transcriptase–polymerase chain reaction, electronic health record documentation or self-report of a positive test, or serology. We also estimated the seroprevalence of SARS-CoV-2 spike and nucleocapsid antibodies measured by ELISA. Overall, 65% of the cohort had ≥ 1 SARS-CoV-2 infection by July 2022, and 19% of those with primary infection were reinfected. Infection and vaccination contributed to high seroprevalence: 98% (95% CI, 95-99) of participants were spike or nucleocapsid seropositive at the end of follow-up. Among those seropositive, 82% were vaccinated. Participants were more likely to be seropositive to spike than nucleocapsid after infection. Infection among seropositive individuals could be identified by increases in nucleocapsid, but not spike, ELISA optical density values. Nucleocapsid antibodies waned more quickly after infection than spike antibodies. High levels of SARS-CoV-2 population immunity, as found in this study, are leading to changing epidemiology necessitating ongoing surveillance and policy evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI 54449, USA.
- Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, WI 53706, USA.
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
ORCID-Profile: Joshua G Petrie, David Pattinson, Jennifer P King, Melissa A Rolfes, Burney A Kieke, Edward A Belongia, Yoshihiro Kawaoka, Huong Q Nguyen
Förderung
- Intramural CDC HHS
Zitieren
APA
Petrie, J. G., Pattinson, D., King, J. P., Neumann, G., Guan, L., Jester, P., Rolfes, M. A., Meece, J. K., Kieke, B. A., Belongia, E. A., Kawaoka, Y., & Nguyen, H. Q. (2025). SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020–July 2022. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwae125
Vancouver
Petrie JG, Pattinson D, King JP, Neumann G, Guan L, Jester P, et al. SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020–July 2022. American Journal of Epidemiology. 2025. doi:10.1093/aje/kwae125
BibTeX
@article{Petrie2025,
author = {Petrie, Joshua G and Pattinson, David and King, Jennifer P and Neumann, Gabriele and Guan, Lizheng and Jester, Peter and Rolfes, Melissa A and Meece, Jennifer K and Kieke, Burney A and Belongia, Edward A and Kawaoka, Yoshihiro and Nguyen, Huong Q},
title = {SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020–July 2022},
journal = {American Journal of Epidemiology},
year = {2025},
doi = {10.1093/aje/kwae125}
}
EUVIMED